156 related articles for article (PubMed ID: 35053843)
1. OKN-007 Alters Protein Expression Profiles in High-Grade Gliomas: Mass Spectral Analysis of Blood Sera.
Towner RA; Hocker J; Smith N; Saunders D; Battiste J; Hanas J
Brain Sci; 2022 Jan; 12(1):. PubMed ID: 35053843
[TBL] [Abstract][Full Text] [Related]
2. Association of decreased levels of lipopolysaccharide-binding protein with OKN-007-induced regression of tumor growth in an F98 rat glioma model.
Smith N; Saunders D; Jensen RL; Towner RA
J Neurosurg; 2019 Oct; 133(6):1695-1703. PubMed ID: 31628293
[TBL] [Abstract][Full Text] [Related]
3. OKN-007 Increases temozolomide (TMZ) Sensitivity and Suppresses TMZ-Resistant Glioblastoma (GBM) Tumor Growth.
Towner RA; Smith N; Saunders D; Brown CA; Cai X; Ziegler J; Mallory S; Dozmorov MG; Coutinho De Souza P; Wiley G; Kim K; Kang S; Kong DS; Kim YT; Fung KM; Wren JD; Battiste J
Transl Oncol; 2019 Feb; 12(2):320-335. PubMed ID: 30468988
[TBL] [Abstract][Full Text] [Related]
4. Regression of glioma tumor growth in F98 and U87 rat glioma models by the Nitrone OKN-007.
Towner RA; Gillespie DL; Schwager A; Saunders DG; Smith N; Njoku CE; Krysiak RS; Larabee C; Iqbal H; Floyd RA; Bourne DW; Abdullah O; Hsu EW; Jensen RL
Neuro Oncol; 2013 Mar; 15(3):330-40. PubMed ID: 23328810
[TBL] [Abstract][Full Text] [Related]
5. OKN-007 decreases tumor necrosis and tumor cell proliferation and increases apoptosis in a preclinical F98 rat glioma model.
de Souza PC; Balasubramanian K; Njoku C; Smith N; Gillespie DL; Schwager A; Abdullah O; Ritchey JW; Fung KM; Saunders D; Jensen RL; Towner RA
J Magn Reson Imaging; 2015 Dec; 42(6):1582-91. PubMed ID: 25920494
[TBL] [Abstract][Full Text] [Related]
6. OKN-007 decreases free radical levels in a preclinical F98 rat glioma model.
Coutinho de Souza P; Smith N; Atolagbe O; Ziegler J; Njoku C; Lerner M; Ehrenshaft M; Mason RP; Meek B; Plafker SM; Saunders D; Mamedova N; Towner RA
Free Radic Biol Med; 2015 Oct; 87():157-68. PubMed ID: 26119786
[TBL] [Abstract][Full Text] [Related]
7. A tale of two multi-focal therapies for glioblastoma: An antibody targeting ELTD1 and nitrone-based OKN-007.
Zalles M; Smith N; Saunders D; Lerner M; Fung KM; Battiste J; Towner RA
J Cell Mol Med; 2022 Jan; 26(2):570-582. PubMed ID: 34910361
[TBL] [Abstract][Full Text] [Related]
8. OKN-007 decreases VEGFR-2 levels in a preclinical GL261 mouse glioma model.
de Souza PC; Smith N; Pody R; He T; Njoku C; Silasi-Mansat R; Lupu F; Meek B; Chen H; Dong Y; Saunders D; Orock A; Hodges E; Colijn S; Mamedova N; Towner RA
Am J Nucl Med Mol Imaging; 2015; 5(4):363-78. PubMed ID: 26269774
[TBL] [Abstract][Full Text] [Related]
9. A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model.
Towner RA; Ihnat M; Saunders D; Bastian A; Smith N; Pavana RK; Gangjee A
BMC Cancer; 2015 Jul; 15():522. PubMed ID: 26177924
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Pediatric Glioblastoma Tumor Growth by the Anti-Cancer Agent OKN-007 in Orthotopic Mouse Xenografts.
Coutinho de Souza P; Mallory S; Smith N; Saunders D; Li XN; McNall-Knapp RY; Fung KM; Towner RA
PLoS One; 2015; 10(8):e0134276. PubMed ID: 26248280
[TBL] [Abstract][Full Text] [Related]
11. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
[TBL] [Abstract][Full Text] [Related]
12. The CHAC1-inhibited Notch3 pathway is involved in temozolomide-induced glioma cytotoxicity.
Chen PH; Shen WL; Shih CM; Ho KH; Cheng CH; Lin CW; Lee CC; Liu AJ; Chen KC
Neuropharmacology; 2017 Apr; 116():300-314. PubMed ID: 27986595
[TBL] [Abstract][Full Text] [Related]
13. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
14. Targeting nitric oxide and NMDA receptor-associated pathways in treatment of high grade glial tumors. Hypotheses for nitro-memantine and nitrones.
Altinoz MA; Elmaci İ
Nitric Oxide; 2018 Sep; 79():68-83. PubMed ID: 29030124
[TBL] [Abstract][Full Text] [Related]
15. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
[TBL] [Abstract][Full Text] [Related]
16. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
[TBL] [Abstract][Full Text] [Related]
17. Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas.
Kim JT; Kim JS; Ko KW; Kong DS; Kang CM; Kim MH; Son MJ; Song HS; Shin HJ; Lee DS; Eoh W; Nam DH
Oncol Rep; 2006 Jul; 16(1):33-9. PubMed ID: 16786120
[TBL] [Abstract][Full Text] [Related]
18. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
19. Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model.
Recinos VR; Tyler BM; Bekelis K; Sunshine SB; Vellimana A; Li KW; Brem H
Neurosurgery; 2010 Mar; 66(3):530-7; discussion 537. PubMed ID: 20173548
[TBL] [Abstract][Full Text] [Related]
20. Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance.
Kitange GJ; Carlson BL; Schroeder MA; Decker PA; Morlan BW; Wu W; Ballman KV; Giannini C; Sarkaria JN
J Neurooncol; 2010 Nov; 100(2):177-86. PubMed ID: 20443131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
